Abstract
Behavioural Science Recommendations
Medication adherence relies on people being able to access and use medication which they are motivated to take. It is influenced by what they know and what they can do (capability); people around them and their physical environment (opportunity); and their beliefs, what they want, how they see themselves, how they regulate emotion, and habit (motivation).
To support changes since COVID-19:
• Consider whether any disruption to daily routines, finances, access to medicines or healthcare and/or social support may make medication adherence more challenging and, where needed, proactively put in place strategies and access to support and services to mitigate these effects,
• Provide resources to address concerns about medication shortages and worries about potential increased risks of taking or not taking treatment,
• Support planning in how to continue to adhere to medication in the event of unpredictable disruptions (e.g. provide information on prescription delivery services in case of need for self-isolation),
• Take the opportunity to offer additional support with medication adherence, particularly if taking medication to optimise health feels more important since COVID-19,
• Given increased use of remote access to clinical care, consider adopting methods to enable remote-monitoring of health including methods to measure and share adherence data with clinical teams so that they can identify and support those who may be having difficulties with medication adherence.
We recommend following the British Psychological Society’s Behavioural Science and Disease Prevention Psychological guidance3 to shape any policy and/or communications strategy.
Medication adherence relies on people being able to access and use medication which they are motivated to take. It is influenced by what they know and what they can do (capability); people around them and their physical environment (opportunity); and their beliefs, what they want, how they see themselves, how they regulate emotion, and habit (motivation).
To support changes since COVID-19:
• Consider whether any disruption to daily routines, finances, access to medicines or healthcare and/or social support may make medication adherence more challenging and, where needed, proactively put in place strategies and access to support and services to mitigate these effects,
• Provide resources to address concerns about medication shortages and worries about potential increased risks of taking or not taking treatment,
• Support planning in how to continue to adhere to medication in the event of unpredictable disruptions (e.g. provide information on prescription delivery services in case of need for self-isolation),
• Take the opportunity to offer additional support with medication adherence, particularly if taking medication to optimise health feels more important since COVID-19,
• Given increased use of remote access to clinical care, consider adopting methods to enable remote-monitoring of health including methods to measure and share adherence data with clinical teams so that they can identify and support those who may be having difficulties with medication adherence.
We recommend following the British Psychological Society’s Behavioural Science and Disease Prevention Psychological guidance3 to shape any policy and/or communications strategy.
| Original language | English |
|---|---|
| Place of Publication | Leicester |
| Publisher | British Psychological Society |
| Commissioning body | British Psychological Society |
| Publication status | Published - 19 Aug 2022 |
Bibliographical note
Co-Chair of the Health Behaviour and COVID-19 working group that produced these documents 7/9UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being -
SDG 17 Partnerships for the Goals
Fingerprint
Dive into the research topics of 'Covid-19 public health road map: Medication adherence'. Together they form a unique fingerprint.Research output
- 5 Commissioned report
-
COVID-19 Public Health Road Map: Eating Behaviour
Whittaker, E., Howlett, N., Abdin, S., Chadwick, P., Shorter, G., Hart, J., Armitage, C., Epton, T., Byrne-Davis, L., Arden, M. A., Kamal, A., Lewis, L., Drury, J., McBride, E., O'Connor, D., Swanson, V., Thompson, S., Chater, A. & Behavioural Science and Disease Prevention Taskforce, 28 Oct 2020, Leicester: British Psychological Society.Research output: Book/Report › Commissioned report
Open Access -
COVID-19 Public Health Road Map: Physical activity
Chater, A., Abdin, S., Dryden, J., Lewis, L., Shorter, G., Arden, M. A., Chadwick, P., Hart, J., Armitage, C., Byrne-Davis, L., Epton, T., Kamal, A., Drury, J., McBride, E., O'Connor, D., Swanson, V., Thompson, S., Whittaker, E., Howlett, N. & Behavioural Science and Disease Prevention Taskforce, 28 Oct 2020, Leicester: British Psychological Society.Research output: Book/Report › Commissioned report
Open Access -
COVID-19 Public Health Road Map: Sedentary behaviour
Chater, A., Abdin, S., Shorter, G., Lewis, L., Hart, J., Armitage, C., Epton, T., Byrne-Davis, L., Arden, M. A., Chadwick, P., Kamal, A., Drury, J., McBride, E., O'Connor, D., Swanson, V., Thompson, S., Whittaker, E., Howlett, N. & Behavioural Science and Disease Prevention Taskforce, Sept 2020, Leicester: British Psychological Society.Research output: Book/Report › Commissioned report
Open Access
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver